News | May 29, 2023
Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Product deliveries scheduled in Q3 of 2023
Unani Medicine facilities to be upgraded at Hyderabad, Chennai, Lucknow, Silchar and Bengaluru
Continues to Expand its Presence in South India
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening & monitoring of Asthma patients
Subscribe To Our Newsletter & Stay Updated
